Improved survival of patients with metastatic breast cancer in routine care: Results of a retrospective study in a community-based oncology group practice 1995-2005

Onkologie

Volumn 32, Issue 3, 2009, Pages 107-113

  Weide, Rudolf ^a,c   Mergenthaler, Ulrike ^b   Pandorf, Annette ^b   Arndt, Holger ^b   Heymanns, Jochen ^a   Thomalla, Jörg ^a   Köppler, Hubert ^a  

^a Praxisklinik fur Hamatologie und Onkologie   (Germany)

^b Institut fur Versorgungsforschung in der Onkologie   (Germany)

^c NONE   (Germany)

Author keywords

Metastatic breast cancer; Routine care; Treatment reality

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GONADORELIN AGONIST; METHOTREXATE; NAVELBINE; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DIARRHEA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; PROGNOSIS; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; COMMUNITY NETWORKS; FEMALE; GERMANY; GROUP PRACTICE; HUMANS; INCIDENCE; MEDICAL ONCOLOGY; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 63849192396     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197360     Document Type: Article

References (19)

1. Hortobagyi GN, Smith TL, Legha SS, Swenerton KD, Gehan EA, Yap HY, Buzdar AU, Blumenschein GR: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1983; 1:776-786.
2. Vogel CL, Azvedo S, Hilsenbeck S, East DR, Ayub J: Survival after first recurrence of breast cancer. The Miami experience. Cancer 1992;70:129-135.
3. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P: Survival of metastatic breast carcinoma patients over a 20-year period. Cancer 2005;104:1742-1750.
4. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN: Is breast cancer survival improving? Cancer 2004;100:44-52.
5. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
6. Klijn JG, Blamey RW, Boccardo F, Tominage T, Duchatreau L, Sylvester R: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2002;20:879-880.
7. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-3767.
8. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109.
9. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998;339:974-984.
10. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ: Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13:197-207.
11. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves L, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
12. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
13. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD: Efficacy of Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-1791.
14. American College of Physicians: Oncology Medical Knowledge Self-Assessment Program. Philadelphia, American College of Physicians, 1999. www.acponline.org.
15. Bernard-Marty C, Cardoso F, Piccart MJ: Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004;9:617-632.
16. Orlando L,Colleoni M, Fedele P, Cusmai A, Rizzo P, D'Amico M, Chetri MC, Cinieri S: Management of advanced breast cancer. Ann Oncol 2007;18(suppl6):vi74- 76.
17. Baltes S, Stegmaier C, Ziegler H, Zimmer J: Brustkrebs. Daten und Trends zu Inzidenz, Mortalität und Überlebenszeiten im Saarland und in Rheinland-Pfalz 1998-2000. www.krebsregister.saarland.de/publikationen/ publik-inhalt.html
18. Weide R, Grass J, Heymanns J, Pandorf A, Kleboth K, Kuppler H: Outpatient therapy in metastatic breast cancer. A retrospective study of 90 patients treated in an oncology group practice. Onkologie 2004;27:380-384.
19. Anderson WF, Reeves JE, Elias A, Berkel H: Out-come of patients with metastatic breast carcinoma treated at a private medical oncology clinic. Cancer 2000;88:95-107.